{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T18:11:28Z","timestamp":1780337488818,"version":"3.54.1"},"reference-count":21,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T00:00:00Z","timestamp":1780099200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hematology Reports"],"abstract":"<jats:p>Background: Treatment options after Bruton\u2019s tyrosine kinase inhibitors (BTKi) failure in Waldenstrom macroglobulinaemia are limited. Methods: We retrospectively analysed the use of bortezomib after BTKi failure in 17 patients who were heavily pre-treated and chemotherapy-exposed at our centre between 2018 and 2025. Results: Reasons for BTKi failure were disease progression (59%) and intolerance (41%). At bortezomib initiation, the median age was 73 years and two patients experienced grade 1\u20132 neuropathy. The best overall response rate (ORR) was 88%. At a median follow up of 39 months (interquartile range 35\u201378), median treatment-free survival and overall survival were 18 (95% confidence interval [CI] 13\u201322) and 22 (95% CI 17\u201345) months, respectively. Conclusion: Bortezomib may be efficacious in patients who experience BTKi failure.<\/jats:p>","DOI":"10.3390\/hematolrep18030036","type":"journal-article","created":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T17:11:01Z","timestamp":1780333861000},"page":"36","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Bortezomib in Patients Who Fail BTKi in Waldenstr\u00f6m Macroglobulinaemia"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4993-7828","authenticated-orcid":false,"given":"Jahanzaib","family":"Khwaja","sequence":"first","affiliation":[{"name":"Department of Haematology, University College London Hospital, London NW1 2BU, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Japzon","sequence":"additional","affiliation":[{"name":"Department of Haematology, University College London Hospital, London NW1 2BU, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Gatto","sequence":"additional","affiliation":[{"name":"Department of Haematology, University Hospital of Wales, Cardiff CF14 4XW, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jindriska","family":"Lindsay","sequence":"additional","affiliation":[{"name":"Department of Haematology, University College London Hospital, London NW1 2BU, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-1545-3137","authenticated-orcid":false,"given":"Charalampia","family":"Kyriakou","sequence":"additional","affiliation":[{"name":"Department of Haematology, University College London Hospital, London NW1 2BU, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shirley","family":"D\u2019Sa","sequence":"additional","affiliation":[{"name":"Department of Haematology, University College London Hospital, London NW1 2BU, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,5,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1111\/bjh.17856","article-title":"Primary therapy and relative survival in patients with lymphoplasmacytic lymphoma\/Waldenstr\u00f6m macroglobulinaemia: A population-based study in the Netherlands, 1989\u20132018","volume":"196","author":"Amaador","year":"2022","journal-title":"Br. J. Haematol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1053\/j.seminhematol.2023.03.005","article-title":"Report of consensus panel 1 from the 11(th) International Workshop on Waldenstrom\u2019s Macroglobulinemia on management of symptomatic, treatment-na\u00efve patients","volume":"60","author":"Buske","year":"2023","journal-title":"Semin. Hematol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.1200\/JCO.22.01805","article-title":"Bortezomib-Dexamethasone, Rituximab, and Cyclophosphamide as First-Line Treatment for Waldenstr\u00f6m\u2019s Macroglobulinemia: A Prospectively Randomized Trial of the European Consortium for Waldenstr\u00f6m\u2019s Macroglobulinemia","volume":"41","author":"Buske","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1053\/j.seminhematol.2025.04.004","article-title":"Report of Consensus Panel 5 from the 12th International Workshop on Waldenstrom\u2019s Macroglobulinemia on the management of patients with intolerance or resistance to covalent BTK inhibitors","volume":"62","author":"Castillo","year":"2025","journal-title":"Semin. Hematol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1182\/blood.2023023639","article-title":"Multiomics analysis of IgM monoclonal gammopathies reveals epigenetic influence on oncogenesis via DNA methylation","volume":"144","author":"Chohan","year":"2024","journal-title":"Blood"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1053\/j.seminhematol.2023.03.003","article-title":"Report of consensus panel 2 from the 11th international workshop on Waldenstr\u00f6m\u2019s macroglobulinemia on the management of relapsed or refractory WM patients","volume":"60","author":"Matous","year":"2023","journal-title":"Semin. Hematol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1038\/s41375-024-02162-5","article-title":"Long-term outcomes by bone marrow B-cell depletion from the R2W trial of bortezomib with cyclophosphamide and rituximab in Waldenstr\u0151m macroglobulinaemia","volume":"38","author":"Counsell","year":"2024","journal-title":"Leukemia"},{"key":"ref_8","first-page":"1655","article-title":"Treatment of relapsed or refractory Waldenstr\u00f6m\u2019s macroglobulinemia with bortezomib","volume":"90","author":"Dimopoulos","year":"2005","journal-title":"Haematologica"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"5099","DOI":"10.1200\/JCO.22.02830","article-title":"Zanubrutinib Versus Ibrutinib in Symptomatic Waldenstr\u00f6m Macroglobulinemia: Final Analysis From the Randomized Phase III ASPEN Study","volume":"43","author":"Dimopoulos","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e70094","DOI":"10.1002\/hem3.70094","article-title":"Salvage treatment after covalent BTKi failure: An unmet need in clinical practice in Waldenstrom macroglobulinemia","volume":"9","author":"Frustaci","year":"2025","journal-title":"Hemasphere"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1182\/blood.2024028164","article-title":"A multiomic analysis of Waldenstr\u00f6m macroglobulinemia defines distinct disease subtypes","volume":"146","author":"Gagler","year":"2025","journal-title":"Blood"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1200\/JCO.2009.25.3237","article-title":"Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom macroglobulinemia","volume":"28","author":"Ghobrial","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_13","first-page":"62","article-title":"Preclinical characterization of pirtobrutinib, a highly selective, noncovalent (reversible) BTK inhibitor","volume":"142","author":"Gomez","year":"2023","journal-title":"Blood"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1200\/JCO.21.00105","article-title":"Combining Ixazomib With Subcutaneous Rituximab and Dexamethasone in Relapsed or Refractory Waldenstr\u00f6m\u2019s Macroglobulinemia: Final Analysis of the Phase I\/II HOVON124\/ECWM-R2 Study","volume":"40","author":"Kersten","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1002\/jha2.597","article-title":"Bortezomib-based therapy is effective and well tolerated in frontline and multiply pre-treated Waldenstr\u00f6m macroglobulinaemia including BTKi failures: A real-world analysis","volume":"3","author":"Khwaja","year":"2022","journal-title":"EJHaem"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1080\/10428194.2017.1307357","article-title":"A phase II Bayesian sequential clinical trial in advanced Waldenstr\u00f6m macroglobulinemia patients treated with bortezomib: Interest of addition of dexamethasone","volume":"58","author":"Leblond","year":"2017","journal-title":"Leuk. Lymphoma"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1182\/blood-2022-159123","article-title":"Efficacy of Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Relapsed\/Refractory Waldenstr\u00f6m Macroglobulinemia: Results from the Phase 1\/2 BRUIN Study","volume":"140","author":"Palomba","year":"2022","journal-title":"Blood"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1111\/bjh.19320","article-title":"A phase II study of ibrutinib in combination with ixazomib in patients with Waldenstr\u00f6m macroglobulinaemia","volume":"204","author":"Parrondo","year":"2024","journal-title":"Br. J. Haematol."},{"key":"ref_19","first-page":"585","article-title":"Identification of 2 DNA methylation subtypes of Waldenstr\u00f6m macroglobulinemia with plasma and memory B-cell features","volume":"136","author":"Giacopelli","year":"2020","journal-title":"Blood"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"4401","DOI":"10.1182\/blood-2023-180109","article-title":"First Results from a Phase 1, First-in-Human Study of the Bruton\u2019s Tyrosine Kinase (BTK) Degrader Bgb-16673 in Patients (Pts) with Relapsed or Refractory (R\/R) B-Cell Malignancies (BGB-16673-101)","volume":"142","author":"Seymour","year":"2023","journal-title":"Blood"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1053\/j.seminhematol.2023.03.009","article-title":"Report of consensus Panel 4 from the 11th International Workshop on Waldenstrom\u2019s macroglobulinemia on diagnostic and response criteria","volume":"60","author":"Treon","year":"2023","journal-title":"Semin. Hematol."}],"container-title":["Hematology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2038-8330\/18\/3\/36\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T17:44:34Z","timestamp":1780335874000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2038-8330\/18\/3\/36"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,30]]},"references-count":21,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["hematolrep18030036"],"URL":"https:\/\/doi.org\/10.3390\/hematolrep18030036","relation":{},"ISSN":["2038-8330"],"issn-type":[{"value":"2038-8330","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,30]]}}}